Economical and pharmacological valuation of pravastatin in secondary coronary prevention;Évaluation pharmaco-économique de la pravastatine dans la prévention coronaire secondaire chez les patients victimes d'infarctus du myocarde ou d'angine de poitrine instable

Medecine et Hygiene

Volumn 57, Issue 2267, 1999, Pages 1667-1673

  Szucs, Thomas D ^a   Bertel, O ^b   Darioli, R ^c   Gutzwiller, F ^e   Mordasini, R ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Klinik Sonnenhof   (Switzerland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ACUTE HEART INFARCTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; REVIEW; SECONDARY PREVENTION;

EID: 0033536475     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bundesamt für Statistik, Hrsg. Statistisches Jahrbuch der Schwiez. Zürich: Verlag Neue Zürcher Zeitung, 1995.
2. Gesetz zur Krankenversicherung (KVG), 1.1.1995, Bern, Eidg. Druckmittel Zentrale
3. Pitt B, Furberg CD, for the PLAC I and PLAC II investigators. Reduction in cardiovascular events during treatment with pravastatin: Pooled analysis from coronary and carotid atherosclerosis intervention trials. Eur Heart J 1994; 15: 2565.
4. Pitt B, Ellis SG, Mancini GBJ, et al. Design and recruitment in the United States of a multiplecenter quantitative angiographic trial of pravastatin to limit atherosclerosis in coronary arteries (PLAC I). Am J Cardiol 1993; 72: 31-5.
5. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Circulation 1995; 92: 2419-25.
6. Scandinavian Simvastatin Survival Study Group (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
7. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group (WOS). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
8. Sack FM, Pfeffer MA, Moye LA, et al. for the cholesterol and recurrent events trial investigators (CARE). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl Med 1996; 335: 1001-9.
9. (white star) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
10. Ashraf T, Hay JW, Pitt B, et al. Cost effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409-14.
11. Berger K, Klose G, Szucs TD. Die Wirtschaftlichkeit von Arzneimiteltherapien. Eine sozioökonomische Analyse der HMG-CoA-Reduktase-Hemmung bei KHK-Patienten am Beispiel von Pravastatin. Med Klin 1997; 92; 363-9.
12. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Eur Heart J 1996; 17: 1001-7.
13. Johannesson M, Jönsson B, Kjekshus J, et al. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6.
14. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol Lowering and the Use of Healthcare Resources: Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1-7.
15. Szucs TD, Guggenberger G, Berger K, et al. Pharmakoökonomische Bewertung von Pravastatin in der koronaren Sekundärprävention bei Patienten. Eine Analyse auf der Grundlage der CARE-Studie. Herz (submitted).
16. Schweizerischer Diagnoseindex, Interkontinental Medical Statistics (IMS), Zug, September 1997.
17. + (vormals VESKA), Aarau, 1997.
18. (white star) Szucs TD, Lüscher TF, Gutzwiller F. Einfluss der medikamentösen Cholesterinsenkung auf den Ressourcenverbrauch im Gesundheitswesen - Bedeutung der Scandinavian Simvastatin Survival Study (4-S Studie) für die Kostenreduktion unter Schweizer Verhältnissen. Schw Med Wschr 1997; 127: 1819-23.
19. (white star)(white star) Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations on reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-41.
20. Beck JR, Kassirer JP, Paufer SG et al. A convenient approximation of life expectancy - the DEALE. I. Validation of the method. Am J Med 1982; 73: 883-8.
21. Beck JR, Kassirer JP, Pauker SG, et al. A convenient approximation of life expectancy - The DEALE. II. Use in medical decision-making. Am J Med 1982, 73, 889-97.
22. (white star) Tengs TO, Adams ME, Pliskin JS. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-90.
23. (white star) Laupacis A, Feeny CD, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Can Med Assoc J 1992; 146: 473-81.
24. (white star)(white star) Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6.
25. WOSCOPS Investigators. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 1998; 97: 1440-5.
26. (white star) Caro J, Klittich W, McGuire A, et al. for the West of Scotland Coronary Prevention Group. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82.
27. Naegeli B, Bertel O, Urban P, et al. Der akute Myokardinfarkt in der Schweiz: Resultate aus dem PIMICS-Herzinfarkt Register. Schweiz med Wschr 1998; 128: 729-36.
28. Szucs T, Berger K, Schulte-Hillen, Kleber FX. Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klinik 1996; 91: 112-8.
29. Goldmann L, Sia STB, Cook EF, et al. Costs and effectiveness of routine therapy with long-term beta-adreneric antagonists after acute myocordial infarction. N Engl J Med 1988; 319: 152-7.
30. Taylor WC, Pass TM, Shephard DS, Komaroff AL. Cost-effectiveness of cholesterol reduction for the primary prevention of coronary heart disease in men. Preventing disease: Beyond the rhetoric. New York: Springer 1990.
31. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732-9.
32. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-31.
33. Owens DK, Harris A, Scott P. Screening Surgeons for HIV Infection. Ann Intern Med 1995; 122: 641-52.
34. Hillner BE, Smith TE. Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991; 324: 160-8.
35. Joyce T, Corman H, Grossman M.: A cost-effectiveness analysis of strategies to reduce infant mortality. Med Care 1988; 26: 348-60.